However, some VHL-mutant ccRCCs were less responsive to HIF2α depletion or HIF2α inhibitor treatment (Choueiri and Kaelin, 2020), suggesting that VHL has other cellular targets that are involved in ccRCC development. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.